52 Percent Of Newly Diagnosed Bipolar Disorder Patients Receive Antidepressant Drugs In First-Line Treatment

Main Category: Bipolar
Also Included In: Psychology / Psychiatry;  Primary Care / General Practice;  Mental Health
Article Date: 16 Sep 2008 - 4:00 PDT

Current ratings for:
'52 Percent Of Newly Diagnosed Bipolar Disorder Patients Receive Antidepressant Drugs In First-Line Treatment'

Patient / Public:4 stars

4 (2 votes)

Healthcare Prof:4 stars

4 (2 votes)


Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 52.3 percent of newly diagnosed bipolar disorder patients are prescribed antidepressant drugs first line.

The new report entitled Treatment Algorithms in Bipolar Disorder finds that this high preponderance of early-line antidepressant use stems from primary care physician prescribing. Surveyed primary care physicians specify selective serotonin reuptake inhibitors (SSRIs)-including Forest Laboratories' Lexapro-as a favored first-line treatment choice for patients with bipolar disorder I with acute depression (51 percent of physicians), bipolar disorder II with acute depression without hypomania (52 percent of physicians) and bipolar disorder II with acute depression with hypomania (46 percent of physicians).

"The number of primary care physicians who are diagnosing and treating bipolar patients has been on the rise in the past few years, but they follow a different treatment pattern than surveyed psychiatrists," said Madhuri Borde, Ph.D., analyst at Decision Resources. "Nearly half of the patients taking SSRIs first line receive these drugs as a monotherapy, despite guideline recommendations to give bipolar patients presenting with depression an antimanic first line."

The report also finds that GlaxoSmithKline's Lamictal is the leading single-agent in first-, second- and third-line therapy amassing 18 percent, 13.8 percent and 16.3 percent patient share in each line of therapy, respectively. Lamictal's patient share in early lines of therapy is driven by psychiatrists' belief that this therapy is effective for patients with bipolar depression.

About Decision Resources

Decision Resources is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

Decision Resources

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions.

Decision Resources, Inc.

View drug information on Lamictal.


Article adapted by Medical News Today from original press release.
Visit our bipolar section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Decision Resources. "52 Percent Of Newly Diagnosed Bipolar Disorder Patients Receive Antidepressant Drugs In First-Line Treatment." Medical News Today. MediLexicon, Intl., 16 Sep. 2008. Web.
23 May. 2012. <http://www.medicalnewstoday.com/releases/121629.php>

APA
Decision Resources. (2008, September 16). "52 Percent Of Newly Diagnosed Bipolar Disorder Patients Receive Antidepressant Drugs In First-Line Treatment." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/121629.php.

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'52 Percent Of Newly Diagnosed Bipolar Disorder Patients Receive Antidepressant Drugs In First-Line Treatment'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Bipolar

Most Popular Articles



Follow Our Bipolar News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Bipolar Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »